In their capacity as directors, contributors, or chairpersons of committees or working groups, the individual leaders and contributors of the IACH must always act in the best interests of the organization and in a manner that preserves the independence and credibility of actions taken on behalf of the IACH. This policy aims to ensure that IACH programs and initiatives are free of bias arising from conflicts of interest.
The IACH directors, contributors, or chairpersons of committees or working groups understand that some circumstances create a conflict of interest when an individual has an opportunity to affect educational content about products or services of a commercial entity any with which he/she has (or has had) a relevant financial relationship.
Therefore, they agree to abide by the following content development mechanism:
- All recommendations for patient care in the IACH educational activities must be based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options.
- Benefits/risks/alternatives for drugs/devices will be given.
- When possible, only scientific or generic names (not trade names) will be used when referring to products.
- Scientific research in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation.
- Unlabeled/off-label or investigational use of any drug/device, and any limitation on the information will be disclosed to learners (e.g., preliminary data, interim analyses, unsupported opinion).
- If they have financial relationships with commercial entities or have had within the past 24 months, the nature of the relationships must be disclosed to the learners before the start of the educational activity. Learners and attendees must also be informed that no relevant financial relationships exist.